Laurus Labs Ltd has reported a robust performance for the second quarter of FY27, with net profit surging 126% year-on-year to Rs 441 crore, driven by strong revenue growth, expanding margins and improved operational performance.

 

Revenue for the quarter rose 33% to Rs 2,206 crore, compared with Rs 1,653 crore in the corresponding period last year. EBITDA jumped 78% to Rs 762 crore from Rs 429 crore, while EBITDA margin expanded sharply to 34.5% from 26% a year ago.

 

Profit before tax (PBT) more than doubled, climbing 119% to Rs 592 crore against Rs 270 crore in Q2 FY26. Diluted earnings per share (EPS) surged 128% to Rs 8.2 from Rs 3.6.

 

The strong quarterly performance was backed by improved gross margins, which increased to 63% from 59.9% in the year-ago quarter.

 

The company also delivered an impressive performance for the first half of FY27, with revenue rising 31% to Rs 4,233 crore from Rs 3,223 crore.

 

H1 EBITDA surged 72% to Rs 1,406 crore, while EBITDA margin expanded to 33.2% from 25.4%. Net profit jumped 126% to Rs 809 crore against Rs 358 crore in the corresponding period last year. PBT more than doubled to Rs 1,073 crore, marking a 117% increase.

 

Commenting on the performance, Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, said: "Laurus achieved another record quarter of strong growth in Revenue and Profits, demonstrating the strength of our CDMO platform and Affordable Medicines portfolio as we execute on our transformation strategy. 

 

"The company operationalized its first commercial scale peptide plant in Vizag utilizing cutting edge operating systems and a significant capacity expansion is already under progress to address surging demand for peptide therapeutics. We also made targeted investments in Oligonucleotides and peptide-resins technologies elevating our integrated CDMO offering. Together this progress reflects our continued commitment on enhancing core capabilities, expanding capacities to deliver greater value for customers and stakeholders.”

 

A key development during the quarter was the operationalisation of Laurus Labs' first commercial-scale peptide manufacturing plant in Visakhapatnam (Vizag). The company is already undertaking a significant capacity expansion to capitalise on rising demand for peptide therapeutics.

 

Laurus Labs also stepped up investments in oligonucleotide and peptide-resin technologies, strengthening its integrated contract development and manufacturing organisation (CDMO) capabilities.

 

The latest results underline the company's strong growth momentum, improving profitability and continued investments in advanced manufacturing technologies as it seeks to expand its presence in the global pharmaceutical and biotechnology markets.